NAS:HCM (Hong Kong)
Business Description
HUTCHMED (China) Ltd
NAICS : 325412
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
Compare
Compare
Traded in other countries / regions
H7T2.Germany
•
00013.Hong Kong
•
HCM.Mexico
•
HCM.UK
•
HCM.USA
Description
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1976.56 | |||||
Equity-to-Asset | 0.67 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.63 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.8 | |||||
3-Year EBITDA Growth Rate | -26.2 | |||||
3-Year EPS without NRI Growth Rate | -29.3 | |||||
3-Year FCF Growth Rate | -64.7 | |||||
3-Year Book Growth Rate | 23 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 27.67 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.47 | |||||
9-Day RSI | 47.75 | |||||
14-Day RSI | 50.61 | |||||
6-1 Month Momentum % | -53.65 | |||||
12-1 Month Momentum % | -68.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.18 | |||||
Quick Ratio | 3.03 | |||||
Cash Ratio | 2.57 | |||||
Days Inventory | 113.36 | |||||
Days Sales Outstanding | 179.79 | |||||
Days Payable | 127.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.1 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 21.67 | |||||
Operating Margin % | -91.26 | |||||
Net Margin % | -64.99 | |||||
ROE % | -10.51 | |||||
ROA % | -7.56 | |||||
ROIC % | -34.36 | |||||
ROC (Joel Greenblatt) % | -272.85 | |||||
ROCE % | -13.81 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.03 | |||||
PB Ratio | 2.9 | |||||
Price-to-Tangible-Book | 2.9 | |||||
EV-to-EBIT | -11.6 | |||||
EV-to-Forward-EBIT | -3.91 | |||||
EV-to-EBITDA | -11.6 | |||||
EV-to-Forward-EBITDA | -3.66 | |||||
EV-to-Revenue | 10.59 | |||||
EV-to-Forward-Revenue | 3.36 | |||||
EV-to-FCF | -20.71 | |||||
Price-to-Projected-FCF | 5.58 | |||||
Price-to-Net-Current-Asset-Value | 3.69 | |||||
Price-to-Net-Cash | 5.31 | |||||
Earnings Yield (Greenblatt) % | -8.62 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:HCM
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 157.362 | ||
EPS (TTM) ($) | -0.7 | ||
Beta | 0.93 | ||
Volatility % | 58.8 | ||
14-Day RSI | 50.61 | ||
14-Day ATR ($) | 0.817897 | ||
20-Day SMA ($) | 13.146 | ||
12-1 Month Momentum % | -68.77 | ||
52-Week Range ($) | 8.405 - 42.93 | ||
Shares Outstanding (Mil) | 172.92 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
HUTCHMED (China) Ltd Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |